Director · Stoke Therapeutics, Inc. · Stoke Therapeutics, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
30.8K
Price
—
Executed
Apr 3, 2026
Disclosed
Apr 7, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Apr 3 executedApr 7, 2026 disclosed
STOK · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Stoke Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
STOK
Shares
30.8K
Price per share
$0
Execution date (reported)
Apr 3, 2026
Owned after transaction
30.8K shares
Days from execution to publication
4
What this establishes
Kahn Clare filed this Form 4 reporting a grant or award of STOK on Apr 3, 2026. It became public on Apr 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Kahn Clarecik:0001849236
Issuer
Stoke Therapeutics, Inc.cik:0001623526
Revision history · 0
No field has changed since this record was first ingested.
